Caris Life Sciences validates AI blood test for cancer detection

IRVING, Texas - Caris Life Sciences (NASDAQ:CAI), a healthcare diagnostics company with a market capitalization of $7.37 billion and annual revenue of $452.5 million, announced Tuesday that a study published in Scientific Reports has validated its Caris Assure blood-based biopsy platform for cancer detection and monitoring.

The study demonstrated the assay’s capabilities across multiple applications, including therapy selection, early cancer detection, and disease monitoring. According to the company, which maintains a healthy gross profit margin of 46.71% and receives a FAIR financial health score from InvestingPro, the platform combines whole exome and whole transcriptome sequencing with machine learning to analyze all 23,000+ genes across DNA and RNA in plasma.

For multi-cancer early detection, the test achieved sensitivities between 83.1% and 95.7% across cancer stages I-IV with 99.6% specificity, according to the study. The platform also demonstrated predictive power for cancer recurrence, with hazard ratios of 33.4 for minimal residual disease and 4.39 for therapeutic monitoring.

"This assay takes advantage of advanced sequencing and computing technology to capture genetic information available from the whole exome and whole transcriptome from the tumor material circulating in the blood and DNA from the patient’s white blood cells," said David Spetzler, President of Caris, in the press release.

The Caris Assure platform was trained on over 376,000 whole exome and whole transcriptome tissue profiles and more than 7,000 matched blood and tissue samples. The company stated that the test does not require a prior tissue biopsy, instead using AI to identify tumor-derived signals based on patterns learned from hundreds of thousands of tumors.

While currently commercially available for therapy selection in advanced cancers, Caris indicated it is pursuing reimbursement and regulatory pathways to expand the platform’s applications to early detection and monitoring. For deeper insights into Caris Life Sciences’ financial health and growth potential, including exclusive ProTips and detailed valuation analysis, visit InvestingPro.

The announcement was based on information provided in a company press release.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.